Abstract:Background The immune-suppressive tumor microenvironment (TME) of oral cancer often hinders the effectiveness of standard treatments, including surgery, chemoradiotherapy, and immunotherapy. This is true for the highly aggressive MOC2 syngeneic oral cancer cell line, which promotes a 'cold' immunological landscape that limits the efficacy of checkpoint inhibition and other immunotherapies. In addition to its direct cytotoxic activity, liposomal doxorubicin (DOXIL) has immune modulatory properties, including modulation of tumor-infiltrating myeloid cell accumulation and polarization. We hypothesized that DOXIL-induced remodeling of the myeloid microenvironment, in combination with radiotherapy, could reverse MOC2 resistance to anti-CTLA-4 and anti-PD-1 checkpoint inhibition. Methods We utilized the well-described MOC2 syngeneic murine model of oral cancer to grow flank tumors. Mice (n=/>20 for each condition, divided over 2–3 experiments) were randomized to each of the following treatments: DOXIL (I.V.), anti-PD-1 (I.P.), anti-CTLA-4 (I.P.), radiation therapy (3 x 8 Gy), and combinations thereof. Treatments began two weeks after MOC2 inoculation. Tumor growth was monitored twice a week and changes in the TME post-treatment were assessed via flow cytometry. We further investigated DOXIL's influence on myeloid differentiation and macrophage polarization by culturing murine bone marrow cells with MOC2-conditioned medium in the presence and absence of DOXIL. Results DOXIL monotherapy potently inhibited tumor growth, but growth resumed shortly after treatment was completed. The combination of DOXIL and anti-CTLA-4, with or without radiation, induced significant anti-tumor activity including complete regressions in most mice. In contrast, anti-CTLA-4 alone or anti-PD-1 and/or radiation (alone or combined with DOXIL) had little effect on tumor growth. Notably, flow cytometry analysis revealed that animals treated with DOXIL displayed nearly a three-fold depletion of MHCII+ macrophages (~23% vs 8% of CD45+ cells. Supporting these observations, in our ex vivo bone marrow cultures, DOXIL also induced a 3–5-fold reduction of the same MHCII+ macrophages, as well a significant decrease in M2 macrophages. Conclusions Our study indicates that in an aggressive, immunologically cold oral cancer model, a combined approach using DOXIL, anti-CTLA-4, and radiation can instigate robust tumor regression. Potential induction of immunogenic cell death and selective macrophage depletion by DOXIL could contribute to the reshaping of the TME, which, in concert with CTLA-4 blockade and radiation, leading to effective anti-tumor responses. This underlines the significance of combination therapies to overcome resistance to immunotherapy in hard to treat cancer models. Ongoing studies are further defining the specific mechanisms by which DOXIL modulates the TME.

Dimethyl Sulfoxide Suppresses Mouse 4T1 Breast Cancer Growth by Modulating Tumor-Associated Macrophage Differentiation.

Altered Hepa1-6 Cells By Dimethyl Sulfoxide (Dmso)-Treatment Induce Anti-Tumor Immunity In Vivo

Low Concentration DMSO Stimulates Cell Growth and In vitro Transformation of Human Multiple Myeloma Cells

Mechanisms Underlying Dimethyl Sulfoxide-Induced Cellular Migration in Human Normal Hepatic Cells.

Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models

Dimethyl Sulfoxide (DMSO) Decreases Cell Proliferation and TNF-α, IFN-γ, and IL-2 Cytokines Production in Cultures of Peripheral Blood Lymphocytes

Dimethyl sulfoxide activates tumor necrosis factorα-p53 mediated apoptosis and down regulates D-fructose-6-phosphate-2-kinase and lactate dehydrogenase-5 in Dalton's lymphoma in vivo

Myeloid-derived Suppressor Cell and Macrophage Exert Distinct Angiogenic and Immunosuppressive Effects in Breast Cancer.

Inhibition of Distinct Steps in the Adipocyte Differentiation Pathway in 3T3 T Mesenchymal Stem Cells by Dimethyl Sulphoxide (DMSO)

Effects of Dimethyl Sulfoxide on Telomerase Activity and Growth of EC9706 Cells

860 CD40 Agonism is Required to Promote the Function of Cross-Presenting Dendritic Cells and Increase Triple Negative Breast Cancer Response to Radiation and CTLA4 Inhibition

CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer

Donkey Milk Inhibits Tumor Growth by Inducing Apoptosis, Pyroptosis and Modulation of Th1/Th2 Responses in a 4T1 Murine Breast Cancer Model

The Implication of Low Dose Dimethyl Sulfoxide on Mitochondrial Function and Oxidative Damage in Cultured Cardiac and Cancer Cells

Study on Apoptosis Induced by DMSO in Human Lung Cancer Cells

Dendrobium officinale polysaccharide promotes M1 polarization of TAMs to inhibit tumor growth by targeting TLR2

Redirecting Immune Activation in the Tumor Microenvironment of Estrogen Receptor Negative Breast Cancer

Synergy and Attenuation Effects of Dihydromyricetin on Tumor-Bearing Mice Affected by Breast Cancer Treated with Chemotherapy

Toll-like Receptor 4 Antagonist Restores Vulnerability of Drug-Tolerant Tumor Cells and Prevents Breast Cancer Metastasis and Post-Surgical Relapse